Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling

Oncogene

Volumn 31, Issue 42, 2012, Pages 4567-4576

  Zeller, C ^a   Dai, W ^a   Steele, N L ^b   Siddiq, A ^c   Walley, A J ^c   Wilhelm Benartzi, C S M ^b   Rizzo, S ^d   Van Der Zee, A ^e   Plumb, J A ^f   Brown, R ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cisplatin; DNA methylation; DNMTi; drug resistance; HDACi; ovarian cancer

Indexed keywords

2 DEOXY 5' AZACYTIDINE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CISPLATIN; UNCLASSIFIED DRUG;

ARGHDIB GENE; ARMCX2 GENE; ARTICLE; CANCER RESISTANCE; COL1A1 GENE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FLNA GENE; FLNC GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; MDK GENE; MEST GENE; MICROARRAY ANALYSIS; MLH1 GENE; NTS GENE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PSMB9 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CISPLATIN; COLLAGEN TYPE I; CPG ISLANDS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; NERVE GROWTH FACTORS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES;

EID: 84867743287     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.611     Document Type: Article

References (50)

1. Agarwal R, Kaye SB. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
2. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. (1996). Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381.
3. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029.
4. Breitling R, Armengaud P, Amtmann A, Herzyk P. (2004). Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92.
5. Broxterman HJ, Gotink KJ, Verheul HM. (2009). Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12: 114-126.
6. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107.
7. Cannistra SA. (2004). Cancer of the ovary. N Engl J Med 351: 2519-2529.
8. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X et al. (2010). Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70: 2870-2879.
9. Dai W, Teodoridis JM, Graham J, Zeller C, Huang TH, Yan P et al. (2008). Methylation linear discriminant analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics 9: 337.
10. Dai W, Teodoridis J, Zeller C, Graham JS, Hersey JM, Flanagan JM et al. (2011). Systematic CpG islands methylation profiling of genes in the Wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17: 4052-4062.
11. Dean M, Fojo T, Bates S. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
12. Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S et al. (2009). Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69: 2996-3003.
13. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA et al. (2008). Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111-1115.
14. Esteller M. (2008). Epigenetics in cancer. N Engl J Med 358: 1148-1159.
15. Gardiner-Garden M, Frommer M. (1987). CpG islands in vertebrate genomes. J Mol Biol 196: 261-282.
16. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. (2004). The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10: 4420-4426.
17. Glasspool RM, Teodoridis JM, Brown R. (2006). Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092.
18. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
19. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
20. Issa JP. (2004). CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993.
21. Johnstone RW, Ruefli AA, Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164.
22. Jones PA, Baylin SB. (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
23. Jung H, Lee SK, Jho EH. (2011). Mest/Peg1 inhibits Wnt signaling via regulation of LRP6 glycosylation. Biochem J 436: 263-269.
24. Kartalou M, Essigmann JM. (2001). Recognition of cisplatin adducts by cellular proteins. Mutat Res 478: 1-21.
25. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP et al. (1988). Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172.
26. Lefebvre L, Viville S, Barton SC, Ishino F, Keverne EB, Surani MA. (1998). Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene Mest. Nat Genet 20: 163-169.
27. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P et al. (2009). Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2: 34.
28. Luqmani YA. (2005). Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1): 35-48.
29. Nakanishi H, Suda T, Katoh M, Watanabe A, Igishi T, Kodani M et al. (2004). Loss of imprinting of PEG1/MEST in lung cancer cell lines. Oncol Rep 12: 1273-1278.
30. O'Brien V, Brown R. (2006). Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 27: 682-692.
31. Ozols RF. (2004). Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. J Natl Compr Canc Netw 2(Suppl 2): S60-S73.
32. Papouli E, Cejka P, Jiricny J. (2004). Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 64: 3391-3394.
33. Pedersen IS, Dervan P, McGoldrick A, Harrison M, Ponchel F, Speirs V et al. (2002). Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet 11: 1449-1453.
34. Peng C, Zhang X, Yu H, Wu D, Zheng J. (2011). Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresis-tance of ovarian cancer. Int J Gynecol Cancer 21: 280-288.
35. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. (2000). Reversal of drug resistance in human tumor xenografts by 2-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044.
36. Rajasekhar VK, Dalerba P, Passegue E, Lagasse E, Najbauer J. (2008). The 5th International Society for Stem Cell Research (ISSCR) Annual Meeting, June 2007. Stem Cells 26: 292-298.
37. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D et al. (2011). Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10: 325-335.
38. Saxonov S, Berg P, Brutlag DL. (2006). A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103: 1412-1417.
39. Schmittgen TD, Livak KJ. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
40. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
41. Smith CA, McClive PJ, Sinclair AH. (2005). Temporal and spatial expression profile of the novel armadillo-related gene, Alex2, during testicular differentiation in the mouse embryo. Dev Dyn 233: 188-193.
42. Steele N, Finn P, Brown R, Plumb JA. (2009). Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100: 758-763.
43. Stojic L, Brun R, Jiricny J. (2004). Mismatch repair and DNA damage signalling. DNA Repair (Amst) 3: 1091-1101.
44. Strathdee G, MacKean MJ, Illand M, Brown R. (1999). A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341.
45. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149.
46. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103: 11154-11159.
47. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J et al. (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967.
48. Wang D, Lippard SJ. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
49. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
50. Yoshioka K, Yoshioka Y, Hsieh P. (2006). ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell 22: 501-510.